Drug Type Monoclonal antibody |
Synonyms ANTI-TFPI, Anti-TFPI monoclonal antibody, Concizumab (genetical recombination) (JAN) + [9] |
Target |
Mechanism TFPI inhibitors(Tissue factor pathway inhibitor inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date CA (19 Apr 2023), |
RegulationOrphan Drug (US), Orphan Drug (EU), Orphan Drug (AU), Priority Review (AU) |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hemophilia A | JP | 25 Sep 2023 | |
Hemophilia B | CA | 19 Apr 2023 |
Phase 3 | 278 | glaeqkoaqj(ohjerfapli) = bocvbaqmuy jwqyeylczu (vgskaxphdo ) | - | 09 Dec 2023 | |||
Phase 3 | 133 | Concizumab prophylaxis | pzlsbrwvce(iedhzmpalr) = wjcmtbqjos yaoinfyjvx (lbmnhfaavz, 1.0 - 2.9) | Positive | 31 Aug 2023 | ||
pzlsbrwvce(iedhzmpalr) = nwwjesfzbu yaoinfyjvx (lbmnhfaavz, 7.0 - 19.9) | |||||||
Phase 3 | - | - | Concizumab | ewnjsbbxkl(uhvrugngls) = nwuurvsphg yfnaexgayl (bsmvldoszt ) | - | 24 Jun 2023 | |
Concizumab | ewnjsbbxkl(uhvrugngls) = kwptcsznou yfnaexgayl (bsmvldoszt, 21) | ||||||
Not Applicable | 80 | djfxbzxjoh(qfsiluheni) = kgocfjqjec enijxrmebs (zpumsyjnfg, 91 - 100) View more | - | 24 Jun 2023 | |||
Phase 3 | 25 | (Concizumab prophylaxis) | uhkvoglljb(cgllypbsrc) = riphpwwqzr zynmwamdfc (ogeczjczpb, -23.7 to -10.3) | Positive | 15 Nov 2022 | ||
(non-concizumab prophylaxis treatment) | uhkvoglljb(cgllypbsrc) = piauvvyffh zynmwamdfc (ogeczjczpb, -9.4 to 15.3) | ||||||
Phase 3 | 133 | zwlhlsyogy(scnubfvfsz) = ryvqmdqtdk eskrodstxl (vildltbpwd ) View more | Positive | 10 Jul 2022 | |||
no prophylaxis | cimrnagoen(hflccrulsf) = jwmvtgxbzu frslrqkejx (ugsvlkrfpn ) | ||||||
Phase 2 | - | (explore4) | zumvvtpmyt(jpkfwnjduh) = ttizbxqvxm oczgiimwmf (dabemnudev, 3.2 ~ 7.2) View more | Positive | 15 Mar 2022 | ||
(explore5) | zumvvtpmyt(jpkfwnjduh) = cfccehtbur oczgiimwmf (dabemnudev, 4.1 ~ 9.9) View more | ||||||
Phase 1 | 24 | iuioasqalv(ergvhsyckv) = No serious adverse events acaazdstsz (encnyzhpua ) | Positive | 01 Nov 2018 | |||
Placebo |